Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The group’s point-of-care Car-T push looks to have stalled.
Minghui’s MHB088C will soon start phase 3 in China.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
